Odense is Denmark's third-largest city and is famed for its green spaces and cycling culture, so Novo Nordisk says it is taking steps to preserve nature at its site and plant more than 4,000 new ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.